Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV-Reference-Cited by-同舟云学术

Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV

Published:2021-07 Issue:7 Volume:10 Page:3093-3105
ISSN:2218-6751
Container-title:Translational Lung Cancer Research
language:
Short-container-title:Transl Lung Cancer Res

Author:

Brueckl Wolfgang M.,Reck Martin,Rittmeyer Achim,Kollmeier Jens,Wesseler Claas,Wiest Gunther H.,Christopoulos Petros,Stenzinger Albrecht,Tufman Amanda,Hoffknecht Petra,Ulm Bernhard,Reich Fabian,Ficker Joachim H.,Laack Eckart

Publisher

AME Publishing Company

Subject

Oncology

Link

https://tlcr.amegroups.com/article/download/53632/pdf

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Efficiency and Safety of Triple-Drug Combination of Albumin-Bound Paclitaxel, Anlotinib and PD-1/L1 Inhibitors in the 2nd or Above Line of Advanced NSCLC: A Retrospective Cohort Study;Cancer Management and Research;2024-08

2. Non–Small Cell Lung Cancer Metastatic Without Oncogenic Alterations;American Society of Clinical Oncology Educational Book;2024-06

3. Antiangiogenese nach Chemoimmuntherapie: eine effektive Option;Pneumo News;2024-04-26

4. Efficacy of ramucirumab combination chemotherapy as second‐line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first‐line therapy;International Journal of Cancer;2024-03-06

5. Development of PET Radioisotope Copper-64-Labeled Theranostic Immunoliposomes for EGFR Overexpressing Cancer-Targeted Therapy and Imaging;International Journal of Molecular Sciences;2024-02-02